期刊文献+

重组人促红细胞生成素聚乙二醇修饰及纯化研究 被引量:5

Modification of Recombinant Human Erythro-protein(EPO) with Polyethylene Glycol(PEG) and Purification of PEG-EPO
下载PDF
导出
摘要 目的 研究重组人促红细胞生成素 (rhEPO)聚乙二醇修饰条件及纯化方法。方法 用SDS PAGE分析不同反应条件对产物成分的影响 ;用红细胞压积法测定各组分的体内生物学活性 ;用分子筛柱层析进行纯化。结果 rhEPO的修饰度随蛋白浓度、蛋白与PEG2 NHS活性酯质量比的增加而提高 ,体内生物学活性随修饰度增加而降低 ,分子筛柱层析纯化效果好。 Objective To explore the condition for the modification of recombinant human erythro poietin (EPO) with polyethylene glycot(PEG) and the method for the purification of PEG EPO.Methods Analyze the influence of various conditions on the components of PEG EPO by SDS PAGE,detect the bioactivity in vivo of PEG EPO by hematocrit method and purify PEG EPO by molecular sieve column chromatography.Results The modification degree of rhEPO increased with the increasing protein concentration as well as the increasing mass ratio of protein to PEG 2 NHS active ester.However,the bioactivity in vivo of PEG EPO decreased with the increasing modification degree.Molecular sieve column showed good purification effect.Conclusion The factors influencing the modification of EPO with PEG were determined,and a purification method for PEG EPO was developed.
出处 《中国生物制品学杂志》 CAS CSCD 2004年第1期23-25,共3页 Chinese Journal of Biologicals
关键词 促红细胞生成素 糖蛋白激素 慢性肾功能衰竭 肿瘤病人 重组 PEG2-NHS活性酯 Recombinant human erythropoietin PEG 2 NHS active ester Polyethylene glycol
  • 相关文献

参考文献11

  • 1[1]Krantz SB. Erythropoietin. Blood,1991,77: 419-443.
  • 2[2]Winearls CG, Oliver DO, Pippard MJ, et al. Effect of humn erythropoietin derived from recombinant DNA on anemic of patients maintained by the chronic haemodialysis. Lancet,1986,11:1175-1184.
  • 3[3]Laemmil UK. Gleavage of structure proteirns during the head of bacteriopluge T4. Nature, 1970;227:680685.
  • 4[4]Smith P K. Measument of protein using bicinchoninic acid. Ana Biochem, 1985,150:76-85.
  • 5[5]Katre NV. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J Immumol, 1990,44: 209-213.
  • 6[6]Morfardini C, Schiavon O, Caliceti P, et al A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem, 1995;6: 62-69.
  • 7[7]Freey R E. Chemical modification of proteins: coments and penspectives. Int Pept Protein Res, 1987,29:145-158.
  • 8[8]Ymaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly (ethylene glycol) with diffent molecular weights after intraenous andministation to mice. J Pharm Sci,1994, 83: 601-606.
  • 9[9]Hershfiield MS. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin Immunol lmnmunopathol,1995,76:228-232.
  • 10[10]Manns MP, McHutchison JG, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatmentt analysis of a multicenter,multinational phase Ⅲ randomized controlled trial. Hepatology, 2000,32: 297A.

同被引文献73

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部